{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:03:33Z","timestamp":1790737413847,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,14]]},"DOI":"10.7759\/cureus.82269","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T04:16:30Z","timestamp":1744690590000},"source":"Crossref","is-referenced-by-count":4,"title":["Cardiovascular Outcomes of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Review of the Current Evidence"],"prefix":"10.7759","author":[{"given":"Priya","family":"Sunkara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga Alekhya","family":"Garikipati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rithish","family":"Nimmagadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjani Mahesh Kumar","family":"Cherukuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himaja","family":"Anne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumitha","family":"Chakilam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepesh","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01525-8","article-title":"Rheumatoid arthritis","volume":"402","author":"Di Matteo A","year":"2023","unstructured":"Di Matteo A, Bathon JM, Emery P. Rheumatoid arthritis. Lancet. 2023, 402:2019-33. 10.1016\/S0140-6736(23)01525-8","journal-title":"Lancet"},{"key":"ref2","article-title":"Rheumatoid arthritis","volume":"392","author":"Haq I","year":"2018","unstructured":"Haq I, McInnes IB. Rheumatoid arthritis. Lancet. 2018, 392:1352-64.","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06628-2","article-title":"Estimation of the global prevalence, incidence, years lived with disability of rheumatoid arthritis in 2019 and forecasted incidence in 2040: results from the Global Burden of Disease Study 2019","volume":"42","author":"Shi G","year":"2023","unstructured":"Shi G, Liao X, Lin Z, Liu W, Luo X, Zhan H, Cai X. Estimation of the global prevalence, incidence, years lived with disability of rheumatoid arthritis in 2019 and forecasted incidence in 2040: results from the Global Burden of Disease Study 2019. Clin Rheumatol. 2023, 42:2297-309. 10.1007\/s10067-023-06628-2","journal-title":"Clin Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k1036","article-title":"Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications","volume":"361","author":"England BR","year":"2018","unstructured":"England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018, 361:k1036. 10.1136\/bmj.k1036","journal-title":"BMJ"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19071890","article-title":"Systemic inflammatory response and atherosclerosis: the paradigm of chronic inflammatory rheumatic diseases","volume":"19","author":"Arida A","year":"2018","unstructured":"Arida A, Protogerou AD, Kitas GD, Sfikakis PP. Systemic inflammatory response and atherosclerosis: the paradigm of chronic inflammatory rheumatic diseases. Int J Mol Sci. 2018, 19:10.3390\/ijms19071890","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000132474.50966.DA","article-title":"Endothelial dysfunction","volume":"15","author":"Endemann DH","year":"2004","unstructured":"Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol. 2004, 15:1983-92. 10.1097\/01.ASN.0000132474.50966.DA","journal-title":"J Am Soc Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1254753","article-title":"Dyslipidemia in rheumatoid arthritis: the possible mechanisms","volume":"14","author":"Yan J","year":"2023","unstructured":"Yan J, Yang S, Han L, et al.. Dyslipidemia in rheumatoid arthritis: the possible mechanisms. Front Immunol. 2023, 14:1254753. 10.3389\/fimmu.2023.1254753","journal-title":"Front Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086069","article-title":"IFN\u03b1 serum levels are associated with endothelial progenitor cells imbalance and disease features in rheumatoid arthritis patients","volume":"9","author":"Rodr\u00edguez-Carrio J","year":"2014","unstructured":"Rodr\u00edguez-Carrio J, de Paz B, L\u00f3pez P, Prado C, Alperi-L\u00f3pez M, Ballina-Garc\u00eda FJ, Su\u00e1rez A. IFN\u03b1 serum levels are associated with endothelial progenitor cells imbalance and disease features in rheumatoid arthritis patients. PLoS One. 2014, 9:e86069. 10.1371\/journal.pone.0086069","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid arthritis - common origins, divergent mechanisms","volume":"388","author":"Gravallese EM","year":"2023","unstructured":"Gravallese EM, Firestein GS. Rheumatoid arthritis - common origins, divergent mechanisms. N Engl J Med. 2023, 388:529-42. 10.1056\/NEJMra2103726","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.812631","article-title":"Effect of anti-rheumatic drugs on cardiovascular disease events in rheumatoid arthritis","volume":"8","author":"Baoqi Y","year":"2021","unstructured":"Baoqi Y, Dan M, Xingxing Z, Xueqing Z, Yajing W, Ke X, Liyun Z. Effect of anti-rheumatic drugs on cardiovascular disease events in rheumatoid arthritis. Front Cardiovasc Med. 2021, 8:812631. 10.3389\/fcvm.2021.812631","journal-title":"Front Cardiovasc Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102401","article-title":"Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies?","volume":"18","author":"Atzeni F","year":"2019","unstructured":"Atzeni F, Svenungsson E, Nurmohamed MT. Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies?. Autoimmun Rev. 2019, 18:102401. 10.1016\/j.autrev.2019.102401","journal-title":"Autoimmun Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.168","article-title":"Cardiovascular safety of biologic therapies for the treatment of RA","volume":"8","author":"Greenberg JD","year":"2011","unstructured":"Greenberg JD, Furer V, Farkouh ME. Cardiovascular safety of biologic therapies for the treatment of RA. Nat Rev Rheumatol. 2011, 8:13-21. 10.1038\/nrrheum.2011.168","journal-title":"Nat Rev Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08213-2","article-title":"Methotrexate and mortality in patients with rheumatoid arthritis:a prospective study","volume":"359","author":"Choi HK","year":"2002","unstructured":"Choi HK, Hern\u00e1n MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis:a prospective study. Lancet. 2002, 359:1173-7. 10.1016\/S0140-6736(02)08213-2","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1185\/030079908x261177","article-title":"The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006","volume":"24","author":"Hochberg MC","year":"2008","unstructured":"Hochberg MC, Johnston SS, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin. 2008, 24:469-80. 10.1185\/030079908x261177","journal-title":"Curr Med Res Opin"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/ar2045","article-title":"Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study","volume":"8","author":"van Halm VP","year":"2006","unstructured":"van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther. 2006, 8:R151. 10.1186\/ar2045","journal-title":"Arthritis Res Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/ar2383","article-title":"Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study","volume":"10","author":"Naranjo A","year":"2008","unstructured":"Naranjo A, Sokka T, Descalzo MA, et al.. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther. 2008, 10:R30. 10.1186\/ar2383","journal-title":"Arthritis Res Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.129916","article-title":"Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis","volume":"70","author":"Greenberg JD","year":"2011","unstructured":"Greenberg JD, Kremer JM, Curtis JR, et al.. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011, 70:576-82. 10.1136\/ard.2010.129916","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024579","article-title":"Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis: an updated meta-analysis","volume":"100","author":"Sun KJ","year":"2021","unstructured":"Sun KJ, Liu LL, Hu JH, Chen YY, Xu DY. Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis: an updated meta-analysis. Medicine (Baltimore). 2021, 100:e24579. 10.1097\/MD.0000000000024579","journal-title":"Medicine (Baltimore)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha R","year":"2011","unstructured":"Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hern\u00e1n MA, Ridker PM, Mozaffarian D. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011, 108:1362-70. 10.1016\/j.amjcard.2011.06.054","journal-title":"Am J Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2015.30.11.1589","article-title":"Effects of methotrexate on carotid intima-media thickness in patients with rheumatoid arthritis","volume":"30","author":"Kim HJ","year":"2015","unstructured":"Kim HJ, Kim MJ, Lee CK, Hong YH. Effects of methotrexate on carotid intima-media thickness in patients with rheumatoid arthritis. J Korean Med Sci. 2015, 30:1589-96. 10.3346\/jkms.2015.30.11.1589","journal-title":"J Korean Med Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/759610","article-title":"Methotrexate, cyclosporine A, and biologics protect against atherosclerosis in rheumatoid arthritis","volume":"2015","author":"Kisiel B","year":"2015","unstructured":"Kisiel B, Kruszewski R, Juszkiewicz A, et al.. Methotrexate, cyclosporine A, and biologics protect against atherosclerosis in rheumatoid arthritis. J Immunol Res. 2015, 2015:759610. 10.1155\/2015\/759610","journal-title":"J Immunol Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B","article-title":"Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group","volume":"44","author":"Cohen S","year":"2001","unstructured":"Cohen S, Cannon GW, Schiff M, et al.. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum. 2001, 44:1984-92. 10.1002\/1529-0131(200109)44:9&lt;1984::AID-ART346&gt;3.0.CO;2-B","journal-title":"Arthritis Rheum"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.93465","article-title":"Antirheumatic drug leflunomide attenuates atherosclerosis by regulating lipid metabolism and endothelial dysfunction via DHODH\/AMPK signaling pathway","volume":"20","author":"Jiang X","year":"2024","unstructured":"Jiang X, Wang W, Lei L, et al.. Antirheumatic drug leflunomide attenuates atherosclerosis by regulating lipid metabolism and endothelial dysfunction via DHODH\/AMPK signaling pathway. Int J Biol Sci. 2024, 20:3725-41. 10.7150\/ijbs.93465","journal-title":"Int J Biol Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002867","article-title":"Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients","volume":"5","author":"Sharma TS","year":"2016","unstructured":"Sharma TS, Wasko MC, Tang X, Vedamurthy D, Yan X, Cote J, Bili A. Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J Am Heart Assoc. 2016, 5:10.1161\/JAHA.115.002867","journal-title":"J Am Heart Assoc"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211836","article-title":"Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"77","author":"Rempenault C","year":"2018","unstructured":"Rempenault C, Combe B, Barnetche T, Gaujoux-Viala C, Lukas C, Morel J, Hua C. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2018, 77:98-103. 10.1136\/annrheumdis-2017-211836","journal-title":"Ann Rheum Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174670","article-title":"In vitro ion channel profile and ex vivo cardiac electrophysiology properties of the R(-) and S(+) enantiomers of hydroxychloroquine","volume":"915","author":"Ballet V","year":"2022","unstructured":"Ballet V, Bohme GA, Brohan E, et al.. In vitro ion channel profile and ex vivo cardiac electrophysiology properties of the R(-) and S(+) enantiomers of hydroxychloroquine. Eur J Pharmacol. 2022, 915:174670. 10.1016\/j.ejphar.2021.174670","journal-title":"Eur J Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI992","article-title":"Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B","volume":"101","author":"Wahl C","year":"1998","unstructured":"Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest. 1998, 101:1163-74. 10.1172\/JCI992","journal-title":"J Clin Invest"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.979300","article-title":"Effect of sulfasalazine on endothelium-dependent vascular response by the activation of Nrf2 signalling pathway","volume":"13","author":"Sonmez MI","year":"2022","unstructured":"Sonmez MI, Shahzadi A, Kose C, Sonmez H, Ozyazgan S, Akkan AG. Effect of sulfasalazine on endothelium-dependent vascular response by the activation of Nrf2 signalling pathway. Front Pharmacol. 2022, 13:979300. 10.3389\/fphar.2022.979300","journal-title":"Front Pharmacol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/art.10228","article-title":"Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial","volume":"46","author":"O'Dell JR","year":"2002","unstructured":"O'Dell JR, Leff R, Paulsen G, et al.. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002, 46:1164-70. 10.1002\/art.10228","journal-title":"Arthritis Rheum"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/art.40366","article-title":"Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease","volume":"70","author":"Eder L","year":"2018","unstructured":"Eder L, Joshi AA, Dey AK, Cook R, Siegel EL, Gladman DD, Mehta NN. Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease. Arthritis Rheumatol. 2018, 70:408-16. 10.1002\/art.40366","journal-title":"Arthritis Rheumatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.12041","article-title":"Anti-tumor necrosis factor-\u03b1 therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis","volume":"126","author":"M\u00e4ki-Pet\u00e4j\u00e4 KM","year":"2012","unstructured":"M\u00e4ki-Pet\u00e4j\u00e4 KM, Elkhawad M, Cheriyan J, et al.. Anti-tumor necrosis factor-\u03b1 therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation. 2012, 126:2473-80. 10.1161\/CIRCULATIONAHA.112.12041","journal-title":"Circulation"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvab005","article-title":"TNF\u03b1 induces endothelial dysfunction in rheumatoid arthritis via LOX-1 and arginase 2: reversal by monoclonal TNF\u03b1 antibodies","volume":"118","author":"Akhmedov A","year":"2022","unstructured":"Akhmedov A, Crucet M, Simic B, et al.. TNF\u03b1 induces endothelial dysfunction in rheumatoid arthritis via LOX-1 and arginase 2: reversal by monoclonal TNF\u03b1 antibodies. Cardiovasc Res. 2022, 118:254-66. 10.1093\/cvr\/cvab005","journal-title":"Cardiovasc Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-12-48","article-title":"Biologics, cardiovascular effects and cancer","volume":"12","author":"Damjanov N","year":"2014","unstructured":"Damjanov N, Nurmohamed MT, Szekanecz Z. Biologics, cardiovascular effects and cancer. BMC Med. 2014, 12:48. 10.1186\/1741-7015-12-48","journal-title":"BMC Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000967","article-title":"Transmembrane tumor necrosis factor alpha attenuates pressure-overload cardiac hypertrophy via tumor necrosis factor receptor 2","volume":"18","author":"Miao K","year":"2020","unstructured":"Miao K, Zhou L, Ba H, et al.. Transmembrane tumor necrosis factor alpha attenuates pressure-overload cardiac hypertrophy via tumor necrosis factor receptor 2. PLoS Biol. 2020, 18:e3000967. 10.1371\/journal.pbio.3000967","journal-title":"PLoS Biol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.802918","article-title":"Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation","volume":"119","author":"Hamid T","year":"2009","unstructured":"Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, Xuan YT, Prabhu SD. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. Circulation. 2009, 119:1386-97. 10.1161\/CIRCULATIONAHA.108.802918","journal-title":"Circulation"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.086157","article-title":"Infliximab improves vascular stiffness in patients with rheumatoid arthritis","volume":"68","author":"Wong M","year":"2009","unstructured":"Wong M, Oakley SP, Young L, et al.. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis. 2009, 68:1277-84. 10.1136\/ard.2007.086157","journal-title":"Ann Rheum Dis"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial","volume":"107","author":"Chung ES","year":"2003","unstructured":"Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003, 107:3133-40. 10.1161\/01.CIR.0000077913.60364.D2","journal-title":"Circulation"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209784","article-title":"Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis","volume":"76","author":"Low AS","year":"2017","unstructured":"Low AS, Symmons DP, Lunt M, et al.. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis. 2017, 76:654-60. 10.1136\/annrheumdis-2016-209784","journal-title":"Ann Rheum Dis"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep251","article-title":"Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis","volume":"48","author":"Galarraga B","year":"2009","unstructured":"Galarraga B, Khan F, Kumar P, Pullar T, Belch JJ. Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford). 2009, 48:1418-23. 10.1093\/rheumatology\/kep251","journal-title":"Rheumatology (Oxford)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201489","article-title":"Etanercept normalises left ventricular mass in patients with rheumatoid arthritis","volume":"72","author":"Da\u00efen CI","year":"2013","unstructured":"Da\u00efen CI, Fesler P, du Cailar G, et al.. Etanercept normalises left ventricular mass in patients with rheumatoid arthritis. Ann Rheum Dis. 2013, 72:881-7. 10.1136\/annrheumdis-2012-201489","journal-title":"Ann Rheum Dis"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/s1388-9842(02)00121-6","article-title":"Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH","volume":"4","author":"Coletta AP","year":"2002","unstructured":"Coletta AP, Clark AL, Banarjee P, Cleland JGF. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur J Heart Fail. 2002, 4:559-61. 10.1016\/s1388-9842(02)00121-6","journal-title":"Eur J Heart Fail"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.5551\/jat.64767","article-title":"Cardiovascular adverse events associated with tumor necrosis factor-alpha inhibitors: a real-world pharmacovigilance analysis","volume":"31","author":"Ma J","year":"2024","unstructured":"Ma J, Cai J, Chen H, Feng Z, Yang G. Cardiovascular adverse events associated with tumor necrosis factor-alpha inhibitors: a real-world pharmacovigilance analysis. J Atheroscler Thromb. 2024, 31:1733-47. 10.5551\/jat.64767","journal-title":"J Atheroscler Thromb"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-013-0064-z","article-title":"Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol","volume":"28","author":"Pasut G","year":"2014","unstructured":"Pasut G. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs. 2014, 28:S15-23. 10.1007\/s40259-013-0064-z","journal-title":"BioDrugs"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000080","article-title":"Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis","volume":"1","author":"Nurmohamed M","year":"2015","unstructured":"Nurmohamed M, Bao Y, Signorovitch J, Trahey A, Mulani P, Furst DE. Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis. RMD Open. 2015, 1:e000080. 10.1136\/rmdopen-2015-000080","journal-title":"RMD Open"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202089","article-title":"Effects of golimumab, an anti-tumour necrosis factor-\u03b1 human monoclonal antibody, on lipids and markers of inflammation","volume":"73","author":"Kirkham BW","year":"2014","unstructured":"Kirkham BW, Wasko MC, Hsia EC, et al.. Effects of golimumab, an anti-tumour necrosis factor-\u03b1 human monoclonal antibody, on lipids and markers of inflammation. Ann Rheum Dis. 2014, 73:161-9. 10.1136\/annrheumdis-2012-202089","journal-title":"Ann Rheum Dis"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170926","article-title":"Cardiovascular (CV) risk after initiation of abatacept versus TNF inhibitors in rheumatoid arthritis patients with and without baseline CV disease","volume":"45","author":"Jin Y","year":"2018","unstructured":"Jin Y, Kang EH, Brill G, Desai RJ, Kim SC. Cardiovascular (CV) risk after initiation of abatacept versus TNF inhibitors in rheumatoid arthritis patients with and without baseline CV disease. J Rheumatol. 2018, 45:1240-8. 10.3899\/jrheum.170926","journal-title":"J Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/354194-cardiovascular-outcomes-of-disease-modifying-antirheumatic-drugs-in-rheumatoid-arthritis-a-review-of-the-current-evidence","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T04:16:32Z","timestamp":1744690592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/354194-cardiovascular-outcomes-of-disease-modifying-antirheumatic-drugs-in-rheumatoid-arthritis-a-review-of-the-current-evidence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":46,"URL":"https:\/\/doi.org\/10.7759\/cureus.82269","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,14]]}}}